{"id":"pioglitazone-vs-metformin","safety":{"commonSideEffects":[{"rate":"common","effect":"Pioglitazone: weight gain"},{"rate":"5-15","effect":"Pioglitazone: fluid retention / edema"},{"rate":"low","effect":"Pioglitazone: increased fracture risk"},{"rate":"20-30","effect":"Metformin: gastrointestinal disturbance (nausea, diarrhea)"},{"rate":"10-30","effect":"Metformin: vitamin B12 deficiency"},{"rate":"<0.1","effect":"Metformin: lactic acidosis (rare)"}]},"_chembl":{"chemblId":"CHEMBL595","moleculeType":"Small molecule","molecularWeight":"356.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pioglitazone acts as a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, enhancing insulin sensitivity in muscle and adipose tissue. Metformin primarily works by activating AMP-activated protein kinase (AMPK), reducing hepatic gluconeogenesis and improving peripheral glucose uptake. Both are first-line agents for type 2 diabetes but differ in mechanism, side effect profile, and clinical outcomes.","oneSentence":"This is a comparative analysis of two marketed diabetes drugs: pioglitazone (a thiazolidinedione that increases insulin sensitivity) versus metformin (a biguanide that reduces hepatic glucose production and improves insulin sensitivity).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:21.931Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (both agents)"},{"name":"Pioglitazone: insulin resistance, metabolic syndrome"},{"name":"Metformin: prediabetes, polycystic ovary syndrome (off-label)"}]},"trialDetails":[{"nctId":"NCT07472179","phase":"NA","title":"Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS","status":"COMPLETED","sponsor":"Mst.Sumyara Khatun","startDate":"2024-08-12","conditions":"PCOS(Insulin Resistant)","enrollment":60},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT06399835","phase":"PHASE4","title":"Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2024-02-01","conditions":"Type 2 Diabetes","enrollment":120},{"nctId":"NCT04419337","phase":"PHASE2","title":"Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-09-15","conditions":"Diabetes Mellitus, Stroke","enrollment":200},{"nctId":"NCT02694263","phase":"PHASE4","title":"Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2016-07","conditions":"Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT02292290","phase":"PHASE4","title":"Trial for People With Established Type 2 Diabetes During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2011-04","conditions":"Type 2 Diabetes","enrollment":99},{"nctId":"NCT00399204","phase":"PHASE4","title":"Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients","status":"WITHDRAWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2006-01","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT00532935","phase":"PHASE3","title":"MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-26","conditions":"Type 2 Diabetes Mellitus","enrollment":517},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT03125694","phase":"PHASE3","title":"Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-02-01","conditions":"Uncontrolled Type 2 Diabetes Mellitus","enrollment":250},{"nctId":"NCT00402909","phase":"PHASE4","title":"Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-11","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT00396227","phase":"PHASE3","title":"Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":2665},{"nctId":"NCT00494312","phase":"PHASE4","title":"Safety Study of Pioglitazone Compared To Glyburide on Liver Function","status":"COMPLETED","sponsor":"Takeda","startDate":"2000-10","conditions":"Diabetes Mellitus, Liver","enrollment":2120},{"nctId":"NCT00384215","phase":"PHASE4","title":"Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-12","conditions":"Diabetes Mellitus, Type 2","enrollment":352},{"nctId":"NCT00308373","phase":"NA","title":"Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2004-07","conditions":"Diabetes Mellitus, Type 2","enrollment":73}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":173,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pioglitazone vs Metformin","genericName":"Pioglitazone vs Metformin","companyName":"Post Graduate Institute of Medical Education and Research, Chandigarh","companyId":"post-graduate-institute-of-medical-education-and-research-chandigarh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a comparative analysis of two marketed diabetes drugs: pioglitazone (a thiazolidinedione that increases insulin sensitivity) versus metformin (a biguanide that reduces hepatic glucose production and improves insulin sensitivity). Used for Type 2 diabetes mellitus (both agents), Pioglitazone: insulin resistance, metabolic syndrome, Metformin: prediabetes, polycystic ovary syndrome (off-label).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}